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Abstract
Background: The choice of antimicrobials for initial treatment of peritoneal dialysis (PD)-related peritonitis is crucial
for a favorable outcome. There is no consensus about the best therapy; few prospective controlled studies have
been published, and the only published systematic reviews did not report superiority of any class of antimicrobials.
The objective of this review was to analyze the results of PD peritonitis treatment in adult patients by employing a
new methodology, the proportional meta-analysis.
Methods: A review of the literature was conducted. There was no language restriction. Studies were obtained from
MEDLINE, EMBASE, and LILACS. The inclusion criteria were: (a) case series and RCTs with the number of reported
patients in each study greater than five, (b) use of any antibiotic therapy for initial treatment (e.g., cefazolin plus
gentamicin or vancomycin plus gentamicin), for Gram-positive (e.g., vancomycin or a first generation cephalosporin), or
for Gram-negative rods (e.g., gentamicin, ceftazidime, and fluoroquinolone), (c) patients with PD-related peritonitis, and
(d) studies specifying the rates of resolution. A proportional meta-analysis was performed on outcomes using a
random-effects model, and the pooled resolution rates were calculated.
Results: A total of 64 studies (32 for initial treatment and negative culture, 28 reporting treatment for Gram-positive
rods and 24 reporting treatment for Gram-negative rods) and 21 RCTs met all inclusion criteria (14 for initial treatment
and negative culture, 8 reporting treatment for Gram-positive rods and 8 reporting treatment for Gram-negative rods).
The pooled resolution rate of ceftazidime plus glycopeptide as initial treatment (pooled proportion = 86% [95% CI
0.82–0.89]) was significantly higher than first generation cephalosporin plus aminoglycosides (pooled proportion = 66%
[95% CI 0.57–0.75]) and significantly higher than glycopeptides plus aminoglycosides (pooled proportion = 75% [95%
CI 0.69–0.80]. Other comparisons of regimens used for either initial treatment, treatment for Gram-positive rods or
Gram-negative rods did not show statistically significant differences.
Conclusion: We showed that the association of a glycopeptide plus ceftazidime is superior to other regimens for initial
treatment of PD peritonitis. This result should be carefully analyzed and does not exclude the necessity of monitoring
the local microbiologic profile in each dialysis center to choice the initial therapeutic protocol.
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Background
Although continuous peritoneal dialysis (PD) was intro-
duced almost four decades ago, its application continues
to be hindered by peritonitis, despite the large reduction
of peritonitis incidence due to advances in connectology
and widespread use of antibiotic prophylaxis. Peritonitis
remains as a serious complication influencing patients’
mortality, and is the most frequent cause of PD failure
[1].
The choice of antimicrobial therapy for initial treatment
is a crucial determinant for a favorable clinical course and
outcome. Historically, this choice has been based on the
recommendations of the International Society for Periton-
eal Dialysis (ISPD), which has published six documents be-
tween 1989 and 2010 [2-7]. According to these guidelines,
the initial treatment of peritonitis (prior to the results of
microbiological tests) should be based on associations of
drugs for coverage of Gram-positive cocci and Gram-
negative bacilli. The recommendations about the class of
antimicrobials have varied over time. In general, for cover-
age of Gram-positive cocci the use of a first generation
cephalosporin or vancomycin has been proposed, while for
Gram-negative bacilli an aminoglycoside or ceftazidime
have been recommended. However, based on the available
literature there is no consensus about the best antimicrobial
therapy for the initial treatment of these infections, and few
prospective and controlled studies have been published.
A systematic review with a meta-analysis of randomized
controlled trials, published by Wiggins et al. [8], included
36 studies published between 1985 and 2006, and did not
report superiority of any class of antimicrobials. One limi-
tation of the study was the exclusion of a large number of
publications with a high number of patients and episodes
of peritonitis. Most of these excluded studies were case
series. Thus, the present study aimed to analyze the clin-
ical results of PD related peritonitis treatment reported in
both, randomized controlled trials (RCTs) and case series
studies employing an alternative methodology, the propor-
tional meta-analysis, and to examine possible differences
among therapeutic protocols.
Methods
Literature search and studies selection
A review of case series and RCTs containing the treat-
ment of PD-related peritonitis was performed. There
was no language restriction. Studies were obtained from
the following sources: US National Library of Medicine
(PUBMED; 1966–2013), Excerpta Medica database
(EMBASE; 1980–2013) and Literatura Latino-Americana
and Caribe em Ciências da Saúde (LILACS; 1982–2013).
The last search date was 11th January, 2013.
The databases were examined using a comprehensive
search strategy for PD-related peritonitis and antibiotic
therapy, along with MeSH and text words, including a
list of synonyms (Appendix). The search strategy was
adapted for each database in order to maximize the abil-
ity to identify eligible studies. The bibliographic refer-
ences in relevant articles were also examined for eligible
studies.
The following inclusion criteria were used: (a) RCTs and
case series studies with a number of reported patients
greater than five, (b) use of any antibiotic therapy, regard-
less of whether it was used for initial treatment (e.g., cefa-
zolin plus gentamicin or vancomycin plus gentamicin), for
Gram-positive rods (e.g., vancomycin or a first generation
cephalosporin), or for Gram-negative rods (e.g., gentami-
cin, ceftazidime, and fluoroquinolone), (c) patients with
PD-related peritonitis, and (d) studies specifying the rates
of peritonitis resolution. The data from RCTs were incor-
porated in the analysis as discrete data sets. Studies in
pediatric patients and those with incomplete data were ex-
cluded from the review.
Peritonitis diagnosis was based on at least two of the fol-
lowing: abdominal pain or cloudy dialysate, dialysate white
cell count >100/μL with at least 50% neutrophilic cells,
and positive culture of dialysate [6,7]. We defined periton-
itis resolution based on the following definitions used by
authors of the included studies: disappearance of signs
and symptoms within 96 h after the beginning of anti-
biotic therapy and a negative peritoneal fluid culture at
least 28 days after treatment completion; an episode of
peritonitis where the catheter remained in situ and symp-
toms and signs resolved; initial response to antibiotic ther-
apy combined with no need to remove the PD catheter;
complete resolution of peritonitis without relapse for
30 days following initial therapy completion; absence of
symptoms of peritonitis and clear dialysate effluent 5 days
after start of antibiotic therapy; sterilization of the dialys-
ate with no relapse within 4 weeks after treatment; no re-
lapse within 2 weeks after ceasing treatment; cure without
altering either of the empirical antibiotics to second-line
antibiotics; resolution of abdominal pain, clearing of di-
alysate, and dialysate neutrophil count less than 100/μL
on day 10; complete resolution of peritonitis by antibiotics
alone without relapse or recurrence within 4 weeks of
completion of therapy; PD fluid became clear, patient sur-
vived the period of the treatment of peritonitis and 4 weeks
after treatment ceased; PD catheter did not require re-
moval to clear the infection, and no relapse of peritonitis
caused by the same organism or with negative culture re-
sults within 4 weeks post treatment of the initial episode
[6,7].
Data collection
Two reviewers independently screened the titles identified
by the literature search, extracted the data from the stud-
ies, and analyzed the results. Discrepancies in the results
were resolved by discussion by the reviewers. A standard
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Table 1 Characteristics of case series and RCT studies including in the qualitative analysis, according to treatment
target (initial, gram-positive and gram-negative rods) and the patient’s renal basal disease
Study All studies Initial treatment/Negative culture Gram + Gram -











No. of patients/No. of episodes 9.268/16.109 4.411/7.315 3,526/6,259 2,549/4,925
Basal renal disease
Branchio-oto-renal syndrome 1 0 0 0
Chronic tubulointerstitial disease 2 1 1 0
Diabetes 51 16 14 10
Glomerulonephritis 33 12 10 6
Gouty 1 1 0 0
Hemolytic-uremic syndrome 1 0 0 0
Hypertension 21 13 8 5
IgA nephropathy 1 1 0 0
Interstitial nephritis 3 1 0 0
Systemic lupus 5 2 1 1
Malignancy 2 0 1 0
Multiple myeloma 1 0 0 0
Nephrosclerosis 2 2 2 0
Obstruction/Reflux 15 5 4 4
Others/unknown 25 11 8 3
Pyelonephritis 4 3 1 1
Policystic kidney disease 24 8 8 5
Renal artery stenosis 1 1 0 0
Renovascular 12 3 1 1
Systemic autoimmune disease 2 2 1 0
Comorbidities
AIDS 1 1 0 0
Cerebrovascular disease 7 1 2 0
Chronic lung disease 7 1 3 1
Connective tissue disorder 1 1 1 0
Congestive heart failure 2 1 1 0
Coronary heart disease 9 1 4 1
Current smoker 4 0 1 0
Dementia 2 1 1 0
Diabetes 16 6 8 5
Hemiplegia 2 1 1 0
Mild liver disease 2 1 1 0
Moderate or severe liver disease 3 2 1 0
Peptic ulcer disease 2 1 1 0
Peripheral vascular disease 9 1 2 0
Secondary hyperparathyroidism 1 0 1 1
Any Tumor, Leukemia, Lymphoma 4 2 3 1
Type of dialysis
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form was used to extract the following information: au-
thors and year of publication, country, number of partici-
pants and peritonitis episodes, patients’ mean age, basal
renal disease, comorbidities, PD modality (continuous am-
bulatory peritoneal dialysis [CAPD] or automated periton-
eal dialysis [APD]), initial peritonitis treatment protocol
and its adjustments, and outcomes.
We used the risk of bias approach for Cochrane Re-
views to assess the RCT quality [9] as we are used to
critical appraise RCT with this tool. Please, find below
the reference. We have included one figure entitled Risk
of bias summary: review authors’ judgments about each
risk of bias item for each RCT included.
Statistical analysis
The outcomes were treated as a dichotomous variable
(peritonitis resolution versus no resolution) with respective
95% confidence intervals (CI). Statistical heterogeneity was
assessed with the I2 statistic, and significance was assumed
when the I2 was greater than 50%. The I2 statistic illustrates
the percentage of the variability in effect estimates resulting
from heterogeneity rather than sampling error [10,11]. Be-
cause of the clear differences among the included studies
and several uncontrolled variables, we used a random-
effect model [12] to perform a proportional meta-analysis
of case series studies [13,14]. The software used to plot the
studies in the meta-analysis was StatsDirect.
For first generation cephalosporins, we included: cefazo-
lin, cephalotin, cefamezin and cephaloridine. The only third
generation cephalosporin we analyzed was ceftazidime. For
aminoglycosides we included gentamicin, amikacin, netil-
micin and tobramycin. Vancomycin and teicoplanin were
considered in the analysis as glycopeptides. Finally, cipro-
floxacin, levofloxacin and ofloxacin were the fluoroquino-
lones included.
A statistically significant difference between interven-
tions was defined when their combined 95% CIs did not
overlap [13,14]. We considered p < 0.05 as statistically
significant.
Results
The literature search was conducted through January 2013,
and 6,743 titles had been identified. After the screening by
title and abstract, we obtained full paper copies of 140
studies reporting antibiotic therapy for PD-related periton-
itis that were eligible for inclusion. However, 56 of these
studies were either cohort or off-topic. Hence, only a total
of 64 case series studies (32 reporting initial treatment and
negative culture, 28 reporting treatment for Gram-positive
rods and 24 reporting treatment for Gram-negative rods)
and 20 RCTs met all inclusion criteria (14 for initial treat-
ment and negative culture, eight reporting treatment for
Gram-positive rods and eight reporting treatment for
Gram-negative rods). These studies included 9.268 patients
with 16.109 episodes of peritonitis. A total of 4.411 patients
(7.315 episodes) were reported for the initial treatment and
negative culture, 3.526 patients (6.259) were reported for
the Gram-positive group, and 2.549 (4.925) were reported
for the Gram-negative group (Table 1).
However, from these total, 38 case series [15-52] were
not included in the meta-analysis due to the lack of data.
Methodological aspects of five RCT studies [53-57] had a
risk of introducing bias, with inadequate blinding of par-
ticipants, random sequence generation and incomplete
outcome, and three RCTs was excluded from the quantita-
tive analysis due to lack of data [53,56,58]. In this way,
proportional meta-analysis was performed from 43 studies
(Figure 1). We have summarized the risk of bias of RCT
included studies in Figure 2.
Comparisons for initial treatment or culture negative
episodes
Ceftazidme plus a glycopeptide as initial treatment was
used in five studies [59-63] with 443 episodes; the pooled
resolution rate was 86% (95% CI 0.82–0.89). This resolution
rate was significant higher than initial treatment with a first
generation cephalosporin plus aminoglycosides (pooled
proportion of 66%, 95% CI 0.57–0.75) from 14 included
studies [57,61,64-75] with 1,438 total episodes (Figure 3).
Initial treatment with ceftazidime plus a glycopeptide also
showed a higher resolution rate than a glycopeptide plus
aminoglycosides (pooled proportion of 75%, 95% CI 0.69–
0.80) that were used in 16 included studies [55,66-68,75-86]
with 574 episodes (Figure 4).
The following comparisons did not show statistically sig-
nificant differences because their CIs overlapped: a first
generation cephalosporin plus aminoglycosides (resolution
rate = 66%, 95% CI 0.57–0.75) versus glycopeptides plus
Table 1 Characteristics of case series and RCT studies including in the qualitative analysis, according to treatment
target (initial, gram-positive and gram-negative rods) and the patient’s renal basal disease (Continued)
CAPD 50 32 24 23
APD 11 7 7 7
Not reported 37 9 11 9
Any change from APD to CAPD NR NR NR NR
Mean age (years) 57,36 55,65 58,44 56,53
NR = not reported; CAPD = continuous ambulatory peritoneal dialysis; APD = automated peritoneal dialysis; RCT = randomized clinical trial.
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aminoglycosides (resolution rate = 75%, 95% CI 0.69–0.80);
a first generation cephalosporin plus aminoglycosides
(resolution rate = 66%, 95% CI 0.57–0.75) versus a first
generation cephalosporin plus ceftazidime (resolution
rate = 59%, 95% CI 0.32–0.83); glycopeptides plus ami-
noglycosides (resolution rate = 75%, 95% CI 0.69–0.80)
versus first generation cephalosporin plus ceftazidime
(resolution rate = 59%, 95% CI 0.32–0.83), and a first
Figure 2 Risk of bias summary of randomized control trials:
review authors' judgments about each risk of bias item for
each included study.
Figure 1 Study flow diagram.
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generation cephalosporin plus ceftazidime (resolution
rate = 59%, 95% CI 0.32–0.83) versus ceftazidime plus a
glycopeptide (resolution rate = 86%, 95% CI 0.82–0.89).
There was significant heterogeneity among studies for
three of the initial treatment used (ceftazidme plus gly-
copeptide I2 = 91.5%; first generation cephalosporin plus
third generation cephalosporin, I2 = 94.8%; third gener-
ation cephalosporin plus glycopeptide, I2 = 8,02E-02% .
Comparisons for episodes due to gram-positive rods
For treatment of episodes due to Gram-positive
rods, the pooled resolution rate from 13 studies
[54,55,62,76,84,85,87-93] with 917 episodes was
78% (95% CI 0.66–0.88) for a glycopeptide, while
from five studies [57,74,88,93,94] with 532 episodes
for a first generation cephalosporin it was 73% (95%
CI 0.55–0.88). There was no significant difference
between the schemes.
There was significant heterogeneity among studies
for both first generation cephalosporin and glycopep-
tide: I2 = 94.6% and 94%, respectively.
Comparisons for episodes due to gram-negative rods
The pooled proportion resolution rate from nine studies
[55,76,85,92,95-98] with 138 episodes was 68% (95% CI
0.50–0.85) for a quinolone (Figure 5). For ceftazidime,
the resolution rate was 61% (95% CI 0.53–0.70) from
three studies [68,56,98] with 117 episodes (Figure 6),
and for aminoglycosides it was 65% (95% CI 0.51–0.77)
from nine studies [55,57,62,68,76,85,90,97,98] with 211
episodes (Figure 7). There were no significant differences
among the three drugs because their CIs overlapped.
There was significant heterogeneity among studies for
both of the two drugs: I2 value was 79.3% for quinolone,
and 71.1% for aminoglycosides.
Discussion
The choice of initial treatment of PD-related peritonitis
remains a challenge to nephrologists who perform PD,
particularly because of the absence of evidence to indicate
superiority of particular recommended therapeutic proto-
cols. Although the only available systematic review with
meta-analysis of randomized clinical trials [8], and its re-
cent update [99] did not show superiority of a specific
class of antimicrobials a review of therapeutic protocols
proposed by ISPD guidelines used in case series studies
(which are typically excluded from meta-analyses) could
potentially show differences in outcomes among anti-
microbial regimens. In addition, the possibility of perform-
ing randomized clinical trials with a sufficient number of
Figure 3 Combined resolution rate with 95% CIs of studies of initial treatment with ceftazidime plus a glycopeptide versus a first
generation cephalosporin plus an aminoglycoside.
Figure 4 Combined resolution rate with 95% CIs of studies of initial treatment with ceftazidime plus a glycopeptide compared to a
glycopeptide plus an aminoglycoside.
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patients has become more remote because of the current
low incidence of PD-related peritonitis.
A narrative review of antimicrobial treatment of patients
with PD-related peritonitis published in 1991 [100] con-
cluded that the optimal empirical treatment was weekly
vancomycin plus ceftazidime. Interestingly, the present
study using proportional meta-analysis of case series was
able to identify the superiority of the combination of gly-
copeptides plus ceftazidime in the initial treatment of PD-
related peritonitis, when compared with a glycopeptide
plus an aminoglycoside and when compared with a first
generation cephalosporin plus aminoglycosides. This re-
sult strongly suggests that the differences found may be
related to a better coverage of Gram-negative bacilli of
Figure 5 Proportional meta-analysis of studies of the resolution rate of quinolone treatment for gram-negative peritonitis.
Figure 6 Proportional meta-analysis of studies of the resolution rate of ceftazidime treatment for gram-negative peritonitis.
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third generation cephalosporin compared with aminogly-
cosides. Bacterial resistance of Gram-negative bacilli, par-
ticularly Pseudomonas species, to commonly prescribed
antimicrobials has been reported in recent years [101]; this
may explain the superiority of the protocols employing
ceftazidime. We found a low-resolution rate associated
with regimens based on aminoglycosides for treatment of
episodes caused by Gram-negatives. It was noticeable that
papers of the decade 90 presenter higher resolution rate
than those published after 2000, which could result of a
temporal increase of bacterial resistance to these antibi-
otics. In agreement, low and decreasing susceptibility rate
of Pseudomonas spp to gentamycin was reported in our
center where only 40% of strains were susceptible in the
same period period [101]. The set of these data suggests
the bacterial resistance may explains the outcome of
Gram-negative episodes treated with aminoglycosides.
The superiority observed with a glycopeptide plus
ceftazidime must be carefully examined, because only
443 peritonitis episodes, in four case series [60-63] and
only one RCT [59] were given this treatment. In
addition, the comparisons among aminoglycosides, cef-
tazidime and fluoroquinolones used for the treatment of
Gram-negative bacilli showed no differences in the reso-
lution rates. Although the majority of these studies did
not report the description of the bacterial resistance pro-
file, differences in resistance may have influenced the
outcome.
The present study confirms previous findings that
showed no differences between vancomycin and first
generation cephalosporins for the treatment of Gram-
positive cocci. However, it should be considered that
an increase in methicillin-resistant coagulase negative
staphylococci as causal agents of PD-related peritonitis
has been reported by several authors [75,102], and that
the results of this review may reflect conditions associ-
ated with the era or specific characteristics of each
center.
This review has several limitations. The most import-
ant is the lower evidence level of case studies compared
with the study designs of studies included in traditional
systematic reviews. In addition, our analysis shows that
there is significant heterogeneity in resolution rate. Finally,
the studies differed considerably in their patient selection,
baseline renal diseases, number of subjects, antibiotic ad-
ministration routes, and other aspects. In conclusion, this
review showed that the protocol of a glycopeptide plus
ceftazidime could be a promising initial therapy in pa-
tients with PD-related peritonitis. This result should be
carefully analyzed, and an emphasis should be placed on
the necessity of monitoring the local microbiologic profile
in each center regarding the initial therapeutic choice.
Conclusion
The association of a glycopeptide plus ceftazidime was
superior to other regimens for initial treatment of PD
peritonitis. This result should be carefully analyzed and
does not exclude the necessity of monitoring the local
microbiologic profile in each dialysis center to choice
the initial therapeutic protocol.
Figure 7 Proportional meta-analysis of studies of the resolution rate of aminoglycosides treatment for gram-negative peritonitis.
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Appendix
Summary of the bibliographic search strategies for type
of clinical situation and intervention of interest.
[(Primary Peritonitis) OR (Secondary Peritonitis) OR
(Peritoneal Dialyses) OR (Peritoneal Dialyses) OR CAPD
OR (Continuous Ambulatory Peritoneal Dialysis) OR
APD OR (Automated Peritoneal Dialysis)] AND [(Anti
Bacterial Agents) OR (Antibacterial Agents) OR (Anti-
Mycobacterial Agents) OR (Anti Mycobacterial Agents)
OR (Antimycobacterial Agents) OR Antibiotic OR Anti-
biotics OR (Bactericidal Agents) OR Bactericides).
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